Carbidopa

BRAND NAMES

• Sinemet – the most widely known formulation

• Sinemet CR – controlled-release version

• Parcopa – orally disintegrating tablet form

MECHANISM OF ACTION

Carbidopa works by blocking the enzyme that converts L-DOPA into dopamine outside the brain. This allows more L-DOPA to reach the brain, where it is turned into dopamine to help control Parkinson’s symptoms, while reducing side effects like nausea and low blood pressure.

PHARMACOKINETICS

Absorption

Carbidopa is quickly absorbed when taken orally, reaching peak blood levels in 1 to 2 hours. It does not cross the blood-brain barrier on its own, so it is always given with L-DOPA, and food may slightly delay absorption but does not reduce its overall effectiveness.

Distribution

Carbidopa has a volume of distribution (Vd) of approximately 0.7–1.0 L/kg, indicating that it is moderately distributed throughout body tissues. It is largely confined to the extracerebral tissues since it does not cross the blood-brain barrier.

Metabolism

Carbidopa is partially broken down in the liver, but most of it remains unchanged and is excreted in the urine. Its minimal metabolism allows it to effectively prevent the breakdown of L-DOPA outside the brain.

Excretion

Carbidopa is primarily excreted through the urine, mostly in unchanged form, with a small portion as metabolites. Its elimination half-life is approximately 1–2 hours, which supports multiple daily doses when used with L-DOPA.

PHARMACODYNAMICS

Carbidopa works by blocking the enzyme that converts L-DOPA to dopamine outside the brain, allowing more L-DOPA to reach the brain. This increases dopamine levels in the central nervous system, improving Parkinson’s symptoms and reducing side effects like nausea and low blood pressure.

ADMINISTRATION

Carbidopa is administered orally, usually in combination with L-DOPA. It comes in tablets, controlled-release tablets, and orally disintegrating tablets, and is typically taken 2 to 3 timesdaily depending on the formulation and the patient’s needs.

DOSAGE AND STRENGTH

Carbidopa is always given in combination with L-DOPA. Common strengths and dosages include:

• Carbidopa 10 mg / L-DOPA 100 mg

• Carbidopa 25 mg / L-DOPA 100 mg

• Carbidopa 25 mg / L-DOPA 250 mg

FOOD INTERACTIONS

Carbidopa has minimal food interactions, but high-protein meals can reduce L-DOPA absorption. To ensure effectiveness, it is best taken 30–60 minutes before or after protein-rich foods.

DRUG INTERACTIONS

Carbidopa can interact with MAO inhibitors, antipsychotics, and iron supplements. These interactions may cause high blood pressure, reduce effectiveness, or decrease L-DOPA absorption, so careful monitoring and dose adjustments are needed.

CONTRAINDICATIONS

• Hypersensitivity to carbidopa or L-DOPA

• Narrow-angle glaucoma

• History of melanoma or suspicious undiagnosed skin lesions

• Concurrent use of non-selective MAO inhibitors

SIDE EFFECTS

• Nausea and vomiting

• Loss of appetite

• Low blood pressure (hypotension)

• Dizziness or lightheadedness

• Dry mouth

• Urinary retention

• Dyskinesia (involuntary movements) with long-term use

OVERDOSE

An overdose of carbidopa/L-DOPA can cause severe nausea, low blood pressure, irregular heartbeat, confusion, and muscle rigidity. Treatment is supportive, focusing on stabilizing vital signs and managing symptoms, and requires immediate medical attention.

TOXICITY

Carbidopa has low toxicity on its own, but high doses of L-DOPA can cause dyskinesia, nausea, low blood pressure, hallucinations, and heart problems. Careful dosing is important to minimize these risks.